Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis

M. Bonfert, F. Heinen, P. Kaňovský, AS. Schroeder, HG. Chambers, E. Dabrowski, TL. Geister, A. Hanschmann, M. Althaus, M. Banach, D. Gaebler-Spira

. 2023 ; 16 (1) : 83-98. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu metaanalýza, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010741

PURPOSE: This pooled analysis of data from three Phase 3 studies investigated the effects of incobotulinumtoxinA on spasticity-related pain (SRP) in children/adolescents with uni-/bilateral cerebral palsy (CP). METHODS: Children/adolescents (ambulant and non-ambulant) were evaluated for SRP on increasingly difficult activities/tasks 4 weeks after each of four incobotulinumtoxinA injection cycles (ICs) using the Questionnaire on Pain caused by Spasticity (QPS; six modules specific to lower limb [LL] or upper limb [UL] spasticity and respondent type [child/adolescent, interviewer, or parent/caregiver]). IncobotulinumtoxinA doses were personalized, with all doses pooled for analysis. RESULTS: QPS key item responses were available from 331 and 155 children/adolescents with LL- and UL-spasticity, respectively, and 841/444 (LL/UL) of their parents/caregivers. IncobotulinumtoxinA efficacy was evident with the first IC. Efficacy was sustained and became more robust with further subsequent ICs. By Week 4 of the last (i.e. fourth) IC, 33.8-53.3% of children/adolescents reported complete SRP relief from their baseline pain for respective QPS items. Children/adolescents reported reductions in mean LL SRP intensity at levels that surpassed clinically meaningful thresholds. Similarly, parents/caregivers observed complete SRP relief and less frequent SRP with incobotulinumtoxinA. Similar results were found for UL SRP. CONCLUSION: These findings indicate that incobotulinumtoxinA could bring considerable benefit to children/adolescents with spasticity by reducing SRP, even during strenuous activities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010741
003      
CZ-PrNML
005      
20230801132620.0
007      
ta
008      
230718s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/PRM-220020 $2 doi
035    __
$a (PubMed)36057802
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bonfert, Michaela $u Division of Paediatric Neurology and Developmental Medicine and LMU Center for Children with Medical Complexity, Dr. von Hauner Children's Hospital, Ludwig Maximilian University of Munich, Munich, Germany
245    10
$a Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis / $c M. Bonfert, F. Heinen, P. Kaňovský, AS. Schroeder, HG. Chambers, E. Dabrowski, TL. Geister, A. Hanschmann, M. Althaus, M. Banach, D. Gaebler-Spira
520    9_
$a PURPOSE: This pooled analysis of data from three Phase 3 studies investigated the effects of incobotulinumtoxinA on spasticity-related pain (SRP) in children/adolescents with uni-/bilateral cerebral palsy (CP). METHODS: Children/adolescents (ambulant and non-ambulant) were evaluated for SRP on increasingly difficult activities/tasks 4 weeks after each of four incobotulinumtoxinA injection cycles (ICs) using the Questionnaire on Pain caused by Spasticity (QPS; six modules specific to lower limb [LL] or upper limb [UL] spasticity and respondent type [child/adolescent, interviewer, or parent/caregiver]). IncobotulinumtoxinA doses were personalized, with all doses pooled for analysis. RESULTS: QPS key item responses were available from 331 and 155 children/adolescents with LL- and UL-spasticity, respectively, and 841/444 (LL/UL) of their parents/caregivers. IncobotulinumtoxinA efficacy was evident with the first IC. Efficacy was sustained and became more robust with further subsequent ICs. By Week 4 of the last (i.e. fourth) IC, 33.8-53.3% of children/adolescents reported complete SRP relief from their baseline pain for respective QPS items. Children/adolescents reported reductions in mean LL SRP intensity at levels that surpassed clinically meaningful thresholds. Similarly, parents/caregivers observed complete SRP relief and less frequent SRP with incobotulinumtoxinA. Similar results were found for UL SRP. CONCLUSION: These findings indicate that incobotulinumtoxinA could bring considerable benefit to children/adolescents with spasticity by reducing SRP, even during strenuous activities.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a mladiství $7 D000293
650    12
$a nervosvalové látky $x terapeutické užití $7 D009465
650    12
$a mozková obrna $x komplikace $x farmakoterapie $7 D002547
650    12
$a botulotoxiny typu A $x terapeutické užití $7 D019274
650    _2
$a svalová spasticita $x farmakoterapie $x etiologie $7 D009128
650    _2
$a bolest $x farmakoterapie $x etiologie $7 D010146
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Heinen, Florian $u Division of Paediatric Neurology and Developmental Medicine and LMU Center for Children with Medical Complexity, Dr. von Hauner Children's Hospital, Ludwig Maximilian University of Munich, Munich, Germany
700    1_
$a Kaňovský, Petr $u Faculty of Medicine and Dentistry and University Hospital, Palacký University Olomouc, Olomouc, Czech Republic
700    1_
$a Schroeder, A Sebastian $u Division of Paediatric Neurology and Developmental Medicine and LMU Center for Children with Medical Complexity, Dr. von Hauner Children's Hospital, Ludwig Maximilian University of Munich, Munich, Germany
700    1_
$a Chambers, Henry G $u Rady Children's Hospital, San Diego, CA, USA
700    1_
$a Dabrowski, Edward $u Beaumont Pediatric Physical Medicine & Rehabilitation -Royal Oak, Royal Oak, MI, USA
700    1_
$a Geister, Thorin L $u Merz Therapeutics GmbH, Frankfurt am Main, Germany
700    1_
$a Hanschmann, Angelika $u Merz Therapeutics GmbH, Frankfurt am Main, Germany
700    1_
$a Althaus, Michael $u Merz Therapeutics GmbH, Frankfurt am Main, Germany
700    1_
$a Banach, Marta $u Department of Neurology, Jagiellonian University Medical College, Krakow, Poland
700    1_
$a Gaebler-Spira, Deborah $u Shirley Ryan Ability Lab, Northwestern Feinberg School of Medicine, Chicago, IL, USA
773    0_
$w MED00208697 $t Journal of pediatric rehabilitation medicine $x 1875-8894 $g Roč. 16, č. 1 (2023), s. 83-98
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36057802 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132616 $b ABA008
999    __
$a ok $b bmc $g 1963286 $s 1197006
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 16 $c 1 $d 83-98 $e - $i 1875-8894 $m Journal of pediatric rehabilitation medicine $n J Pediatr Rehabil Med $x MED00208697
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace